Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 8/20 | 0.44 |
| ▸ | RAB9A | P51151 | 8/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.44 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.43 |
| ▸ | NOTUM | Q6P988 | 5/20 | 0.39 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.38 |
| ▸ | NFKB1 | P19838 | 3/20 | 0.36 |
| ▸ | NFKB2 | Q00653 | 3/20 | 0.36 |
| ▸ | RELA | Q04206 | 3/20 | 0.36 |
| ▸ | HPGD | P15428 | 3/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | CASP1 | P29466 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3475309 | 0.80 | TP53 (0.46) | NPC1RAB9ASMN1; SMN2NOTUMATAD2 | |
| SCHEMBL1546047 | 0.78 | NPC1 (0.48) | NPC1RAB9ASMN1; SMN2NOTUMALOX15 | |
| SCHEMBL5552360 | 0.78 | NPC1 (0.42) | NPC1RAB9ASMN1; SMN2NR1H4NOTUM | |
| SCHEMBL4159658 | 0.78 | CHRNB2 (0.51) | NPC1RAB9ASMN1; SMN2HPGDALOX15 | |
| SCHEMBL5553615 | 0.77 | NOTUM (0.49) | NOTUMMEN1KMT2AALDH1A1KDM4E | |
| SCHEMBL5553581 | 0.77 | NPC1 (0.50) | NPC1RAB9ASMN1; SMN2NOTUMNFKB1 | |
| SCHEMBL5552349 | 0.77 | RAB9A (0.50) | NPC1RAB9ASMN1; SMN2NOTUMHPGD | |
| SCHEMBL3965118 | 0.74 | LMNA (0.44) | NPC1RAB9ASMN1; SMN2NOTUMHPGD | |
| SCHEMBL6135425 | 0.74 | RAB9A (0.46) | NPC1RAB9ASMN1; SMN2NR1H4NOTUM | |
| SCHEMBL2333242 | 0.74 | NPC1 (0.47) | NPC1RAB9ASMN1; SMN2NR1H4NOTUM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 322 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110372626-B | Method for preparing 1,2, 4-oxadiazole compound | 河南大学 | 2022-11-08 | — | — | CN | claimed |
| CN-107889487-B | Bicyclic tetrahydrothiazepine derivatives for the treatment of tumor and/or infectious diseases | 阿派隆生物制剂股份公司 | 2021-09-03 | — | — | CN | claimed |
| US-10472341-B2 | Bicyclic tetrahydrothiazepine derivatives useful for the treatment of neoplastic and/or infectious diseases | APEIRON BIOLOGICS AG (AT) | 2019-11-12 | — | — | US | claimed |
| US-20180170888-A1 | BICYCLIC TETRAHYDROTHIAZEPINE DERIVATIVES USEFUL FOR THE TREATMENT OF NEOPLASTIC AND/OR INFECTIOUS DISEASES | APEIRON BIOLOGICS GMBH (AT) | 2018-06-21 | — | — | US | claimed |
| EP-3265463-A1 | BICYCLIC TETRAHYDROTHIAZEPINE DERIVATIVES USEFUL FOR THE TREATMENT OF NEOPLASTIC AND/OR INFECTIOUS DISEASES | Apeiron Biologics AG (AT) | 2018-01-10 | — | — | EP | claimed |
| US-9487494-B2 | Cyclic hydrocarbon compounds for the treatment of diseases | LEO PHARMA A/S (DK) | 2016-11-08 | — | — | US | claimed |
| CN-102725290-A | Fused heterocyclic compounds as ion channel modulators | GILEAD PALO ALTO INC | 2012-10-10 | — | — | CN | claimed |
| US-20110269761-A1 | ARYLSULPHONYLGLYCINE DERIVATIVES, THE PREPARATION THEREOF AND THEIR USE AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-11-03 | — | — | US | claimed |
| EP-2279173-A1 | NEW ARYLSULPHONYLGLYCINE DERIVATIVES, THE PREPARATION THEREOF AND THEIR USE AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-02-02 | — | — | EP | claimed |
| US-20100317582-A1 | NOVEL CYCLIC HYDROCARBON COMPOUNDS FOR THE TREATMENT OF DISEASES | LEO PHARMA A/S (DK) | 2010-12-16 | — | — | US | claimed |
| WO-1999058504-A1 | NOVEL 1,2,5-TRISUBSTITUTED 1,2-DIHYDRO-INDAZOL-3-ONES WITH ANTI-ASTHMATIC, ANTI-ALLERGIC, ANTI-INFLAMMATORY, IMMUNO-MODULATING AND NEURO-PROTECTIVE EFFECT, METHOD FOR THE PRODUCTION AND USE THEREOF AS A MEDICAMENT | ARZNEIMITTELWERK DRESDEN GMBH (DE) | 1999-11-18 | — | — | WO | claimed |
| WO-1999045006-A1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF ROTAMASE ENZYMES | PFIZER INC. (US) | 1999-09-10 | — | — | WO | claimed |
| US-5728704-A | INHIBITS SORBITOL DEHYDROGENASE | PFIZER INC. (US) | 1998-03-17 | — | — | US | claimed |
| EP-0662962-A1 | SUBSTITUTED PYRIMIDINES FOR CONTROL OF DIABETIC COMPLICATIONS | PFIZER INC. (US) | 1995-07-19 | — | — | EP | claimed |
| EP-0401981-B1 | Pyridazinone deriratives | PFIZER (US) | 1995-04-26 | — | — | EP | claimed |
| WO-1994007867-A1 | SUBSTITUTED PYRIMIDINES FOR CONTROL OF DIABETIC COMPLICATIONS | PFIZER INC. (US) | 1994-04-14 | — | — | WO | claimed |
| EP-0582643-A1 | PYRIDAZINONE ACETIC ACIDS | PFIZER INC. (US) | 1994-02-16 | — | — | EP | claimed |
| WO-1992017446-A2 | PYRIDAZINONE ACETIC ACIDS ALDOSE REDUCTASE INHIBITORS | PFIZER INC. (US) | 1992-10-15 | — | — | WO | claimed |
| US-4996204-A | Antidiabetic agents | PFIZER INC. (US) | 1991-02-26 | — | — | US | claimed |
| EP-0401981-A1 | Pyridazinone deriratives | PFIZER INC. (US) | 1990-12-12 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317582-A1 | NOVEL CYCLIC HYDROCARBON COMPOUNDS FOR THE TREATMENT OF DISEASES | ARNT, AHR, CYP27A1 | NPC1 190/4885RAB9A 4614/4885SMN1; SMN2 3310/4885 |
| US-10472341-B2 | Bicyclic tetrahydrothiazepine derivatives useful for the treatment of neoplastic and/or infectious diseases | CCNT2, HRH4, HRH3 | NPC1 563/4885RAB9A 3560/4885SMN1; SMN2 3392/4885 |
| US-20110269761-A1 | ARYLSULPHONYLGLYCINE DERIVATIVES, THE PREPARATION THEREOF AND THEIR USE AS MEDICAMENTS | SULT2A1, UGT1A1, SLC5A1 | NPC1 1879/4885RAB9A 2091/4885SMN1; SMN2 2627/4885 |
| US-20180170888-A1 | BICYCLIC TETRAHYDROTHIAZEPINE DERIVATIVES USEFUL FOR THE TREATMENT OF NEOPLASTIC AND/OR INFECTIOUS DISEASES | CCNT2, HRH4, HRH3 | NPC1 563/4885RAB9A 3560/4885SMN1; SMN2 3392/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.